Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$454.4M
133M shares
52-week range
$0.92 – $13.40
17% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
180.09%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $859.0K | $854.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$859.0K | −$854.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $35.4M | $26.7M | $2.7M | $2.5M | $6.3M | $7.6M | $7.3M | $9.3M |
| Operating income | −$43.3M | −$34.9M | −$3.6M | −$7.7M | −$14.9M | −$16.4M | −$15.4M | −$19.8M |
| EBITDA | −$42.6M | −$46.1M | −$3.6M | −$7.7M | −$14.3M | −$15.4M | −$15.0M | −$20.8M |
| Net income | −$43.5M | −$47.6M | −$3.6M | −$7.7M | −$14.3M | −$15.4M | −$15.0M | −$20.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -111.67 | -112.74 | -0.66 | -1.89 | -1.73 | -1.84 | -1.61 | -21.58 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-6.34 | $-6.34–$-6.34 | 1 |
| 2027 | $0 | $-4.42 | $-4.42–$-4.42 | 1 |
| 2028 | $42M | $0.79 | $0.79–$0.79 | 1 |
| 2029 | $123M | $6.40 | $6.40–$6.40 | 1 |
Forward consensus · source: Financial Modeling Prep
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
www.indaptusrx.comNo one on the platform currently holds INDP.
No tracked institution reports a position in INDP as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-06-27 | 1-for-28reverse |
| 2021-07-27 | 1-for-4reverse |
| 2020-10-30 | 1-for-20reverse |
No one on the platform has traded INDP yet.
| $268009 |
| — |
| NKGNNKGen Biotech, Inc. Common Stock | $0.06 | +0.00% | $8M | — |
| PBMPsyence Biomedical Ltd. | $3.10 | +4.38% | $58959 | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$INDP How could the company's webpage like this for several months? Is it against SEC rules?
View on StockTwits ↗$INDP it's the fifth time last 12 month they followed this pattern they drop to under 2$ then get back to 3.50$ that's up 75% then down 45%
View on StockTwits ↗$INDP sold 20 million shares in a private placement, raising about $12 million at $0.60 per share.
View on StockTwits ↗$INDP SEC filing https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315226029918/form8-k.htm Company agreed to issue & sell 20m shares at $0.60 in a private placement. Gross proceeds $12M.
View on StockTwits ↗$INDP Shareholder meeting scheduled July 28 https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315226029633/formpre14a.htm Proposals: 1) Elect David Natan, Tim Ruan, and Johnny Fox Arrowsmith (Yi Zhang) as Class II Directors 2) Ratify Haskell & White LLP as independent accounting firm 3) Approve the 2026 Equity Incentive Plan 4) Approve the issuance of shares in one or more private placements for gross proceeds of up to $300M at purchase prices ranging from $0.60 to $1.00 per share. Such financings must be completed within 12 months of shareholder approval. Shareholders of record on June 12 are entitled to vote. There were 113,242,324 shares outstanding as of the record date.
View on StockTwits ↗$INDP makes s great swing trade for me come join me in a free discord link in my stoctwits Profile my bullish 🐂 peeps
View on StockTwits ↗$INDP golden cross incoming on daily
View on StockTwits ↗Top Stocks to watch tomorrow 1 / 2: $GPUS $INDP $RXT $ICCM $CAST ICCM: Looking good on 4hours chart. Key support zone at 4.70 - 5.10. Next key level to test 7.15 - 7.55. Currently at 6.08 GPUS: Initially alerted at 0.27. Currently at 0.46. Trending nicely on daily chart. Updated support zone at 0.33 - 0.36 now. Next key level to test 0.56 - 0.6. RXT: Good close of daily candle. 5.8 - 6.2 is acting as key support zone. Next key level to test 8.7 - 9.3. Currently at 7.66. It has long term potential of 12+ CAST: Initially alerted at 1.41. Currently at 4.61. Still looking good on 4hours chart with updated support zone at 3.40 - 3.70. Next key level to test 5.45 - 5.8. INDP: Initially alerted at 3.62. Currently at 4.50. Looking good on daily chart. Key support zone at 3.45 - 3.7. Next key level to test 5.15 - 5.50.
View on StockTwits ↗$INDP the price action continues to strengthen.
View on StockTwits ↗Here is my Amazing daily "Stocktwits" report: $OBAI $INDP $GPUS $SRXH $BTQ OBAI Price 0.93. My post last night "Looking good on 4hours chart. Key support zone at 0.69 - 0.74. Next key level to test 1.22 - 1.35." It made a nice move to 1.52 today INDP Price 3.62. My post was "2.55 - 2.75 is acting as key support zone. Next key level to test 4.15 - 4.45." It hit our desired zone, went till 4.94 today GPUS Price 0.27. My post was "Looking good on 4hours chart. Key support zone at 0.2 - 0.2230. Next key level to test 0.33 - 0.36." It hit our desired zone, went till 0.4421 today SRXH Price 0.20. My post last night "Looking good on daily chart with key support at 0.14 - 0.1530. Next key level to test 0.2450 - 0.27." It hit our desired zone, went till 0.2497 today BTQ Price 5.39. My post was "Looking good on daily chart. 4.25 - 4.55 is acting as key support zone. Next key level to test 6.15 - 6.50." It hit our desired zone, went till 6.22 today
View on StockTwits ↗$INDP $CVKD $ARTV $REPL $RCKT investing in their future!
View on StockTwits ↗Mid-Day Update 🚀 🎯 Levels respected perfectly: $ICCM → called at 6.46 → went till 9.53 (+48%)🔥 $OBAI → called at 0.93 → went till 1.52 (+63%)📈 $INDP → called at 3.62 → went till 4.45 (+23%)🚀 $GPUS → called at 0.27 → went till 0.3680 (+36%)✅ $SRXH → called at 0.20 → went till 0.2497 (+25%)🔥 All levels shared earlier (in detailed posts) and reacting cleanly.
View on StockTwits ↗$INDP who is holding all the float with only 3 million to trade ?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.